NINDS Transverse Myelitis Information Page

No effective cure currently exists for people with transverse myelitis.  Physicians often prescribe corticosteroid therapy during the first few weeks of illness to decrease inflammation.  Following initial therapy, the most critical part of the treatment for this disorder consists of keeping the patient’s body functioning while hoping for either complete or partial spontaneous recovery of the nervous system.  If an individual begins to recover limb control, physical therapy begins to help improve muscle strength, coordination, and range of motion.

Recovery from transverse myelitis usually begins within 2 to 12 weeks of the onset of symptoms and may continue for up to 2 years. However, if there is no improvement within the first 3 to 6 months, significant recovery is unlikely. About one-third of people affected with transverse myelitis experience good or full recovery from their symptoms.  Another one-third show only fair recovery and are left with significant deficits.  The remaining one-third show no recovery at all, with marked dependence on others for basic functions of daily living.

The National Institute of Neurological Disorders and Stroke (NINDS) conducts research related to transverse myelitis in its laboratories at the National Institutes of Health (NIH), and also supports additional transverse myelitis research through grants to major medical institutions across the country.  Some studies focus on strategies to repair the spinal cord, including approaches using cell transplantation.  The NINDS also funds researchers who are using animal models of spinal cord injury to study strategies for replacement or regeneration of spinal cord nerve cells.  The knowledge gained from such research should lead to a greater knowledge of the mechanisms responsible for transverse myelitis and may ultimately provide a means to prevent and treat this disorder.